Entremed (ENMD)

[nottadoc2]

Probably the most significant to us would be this quote from Dr. Bray, VP:

"Recently, the Company
completed enrollment for the Phase 2 study in ovarian cancer patients and, once the data have been analyzed, intends to present results of the study at an upcoming scientific meeting."

Apparently it did take longer to reach full enrollment than they originally anticipated. Perhaps that is why they expanded to include the fallopian and other cxancer patients with tumors in the same neighborhood. No doubt this announcement is PR with an eye to bolstering the stock price--the P 1 data was already availasble to the oncology community--and that more than one pt. has dropped out due to progressive disease. That said, if the preliminary phase 2 results were statistically awful, why would they take this optimistic tone now only to invite greater embarassment later ? It shouldn't take long to "analyze the data", so when is the next scientific meeting at which the results could be presented ?